Mainz Biomed (MYNZ) announces that ColoAlert, its non-invasive colorectal cancer screening test, has been officially registered and approved for distribution by Swissmedic, the Swiss regulatory and supervisory authority for medicinal products and medical devices. The regulatory approval by Swissmedic follows the Company’s previously announced partnership with a local laboratory in Switzerland, labor team w ag, earlier this year. With this milestone, ColoAlert is now authorized for use in the Swiss market and will be made available through the partner laboratory’s diagnostic service offering, with no remaining obstacles to the upcoming launch.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYNZ:
- Mainz Biomed Secures $3 Million Through Securities Purchase Agreement
- Mainz Biomed files to sell 1.47M ordinary units
- Mainz Biomed, CARE announce collaboration agreement
- Mainz Biomed reviews accomplishments for first half of 2025
- Mainz Biomed secures public funding to advance pancreatic cancer screening test